Literature DB >> 12354835

Screening for hepatocellular carcinoma.

Ayman Koteish1, Paul J Thuluvath.   

Abstract

To determine the role of screening and to screen in a cost-effective manner, it is important to define the high-risk patient population that is most likely to benefit from screening and to identify a readily available diagnostic modality that is sensitive, specific, and inexpensive. Moreover, to have a major effect on the outcome of hepatocellular carcinoma, the test should be applicable in the majority of high-risk subjects. Herein, we identify the high-risk patient population, discuss various diagnostic modalities, and recommend a practical and cost-effective strategy for screening.

Entities:  

Mesh:

Year:  2002        PMID: 12354835     DOI: 10.1016/s1051-0443(07)61785-0

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  12 in total

1.  Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.

Authors:  Neil Mehta; Monika Sarkar; Jennifer L Dodge; Nicholas Fidelman; John P Roberts; Francis Y Yao
Journal:  Liver Transpl       Date:  2016-01-08       Impact factor: 5.799

Review 2.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

3.  CISD2 associated with proliferation indicates negative prognosis in patients with hepatocellular carcinoma.

Authors:  Bin Chen; Shunli Shen; Jian Wu; Yunpeng Hua; Ming Kuang; Shaoqiang Li; Baogang Peng
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Diagnosis of hepatocellular carcinoma.

Authors:  Eldad S Bialecki; Adrian M Di Bisceglie
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

5.  An overview of biomarkers for the diagnosis of hepatocellular carcinoma.

Authors:  Mona Abu El Makarem
Journal:  Hepat Mon       Date:  2012-10-20       Impact factor: 0.660

6.  Diagnosis of hepatoma using grayscale and Doppler ultrasound in patients with chronic liver disease.

Authors:  Wasim A Memon; Zishan Haider; Mirza Amanullah Beg; Muhammad Idris; Tanveer-Ul-Haq Waseem Akhtar; Sidra Idris
Journal:  Int J Gen Med       Date:  2011-10-31

7.  Clinical significance and therapeutic value of glutathione peroxidase 3 (GPx3) in hepatocellular carcinoma.

Authors:  Xiang Qi; Kevin Tak Pan Ng; Qi Zhou Lian; Xiao Bing Liu; Chang Xian Li; Wei Geng; Chang Chun Ling; Yuen Yuen Ma; Wai Ho Yeung; Wen Wei Tu; Sheung Tat Fan; Chung Mau Lo; Kwan Man
Journal:  Oncotarget       Date:  2014-11-30

8.  Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients.

Authors:  Joon Yeul Nam; Jeong-Hoon Lee; Hwi Young Kim; Jieun E Kim; Dong Hyeon Lee; Young Chang; Hyeki Cho; Jeong-Ju Yoo; Minjong Lee; Young Youn Cho; Yuri Cho; EunJu Cho; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

9.  HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.

Authors:  A M Attallah; M M Omran; A A Attallah; S O Abdallah; K Farid; H Darwish; I El-Dosoky; Y M Shaker
Journal:  Br J Cancer       Date:  2013-08-27       Impact factor: 7.640

10.  A novel model of liver cancer stem cells developed from induced pluripotent stem cells.

Authors:  Said M Afify; Anna Sanchez Calle; Ghmkin Hassan; Kazuki Kumon; Hend M Nawara; Maram H Zahra; Hager M Mansour; Apriliana Cahya Khayrani; Md Jahangir Alam; Juan Du; Akimasa Seno; Yoshiaki Iwasaki; Masaharu Seno
Journal:  Br J Cancer       Date:  2020-03-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.